Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
13F holders, Q3 2022
Institutional positions in Navidea Biopharmaceuticals, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- −1 vs. Q2 2022
- Shares held
- 1.51M
- +5.19K (+0.3%) vs. Q2 2022
- Total value
- $379.6K
- −$698.7K (−64.8%) vs. Q2 2022
- New holders
- 3
- 4 more added
- Sold out
- 4
- 4 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 2 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 1 | $0 |
| Q1 2025 | 2 | $0 |
| Q4 2024 | 1 | $0 |
| Q3 2024 | 2 | $0 |
| Q2 2024 | 2 | $0 |
| Q1 2024 | 2 | $13 |
| Q4 2023 | 4 | $469 |
| Q3 2023 | 24 | $225.8K |
| Q2 2023 | 23 | $138.5K |
| Q1 2023 | 30 | $364.4K |
| Q4 2022 | 28 | $339.3K |
| Q3 2022 | 25 | $379.6K |
| Q2 2022 | 26 | $1.08M |
| Q1 2022 | 25 | $1.19M |
| Q4 2021 | 31 | $1.68M |
| Q3 2021 | 29 | $2.76M |
| Q2 2021 | 31 | $3.08M |
| Q1 2021 | 35 | $3.77M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Navidea Biopharmaceuticals, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 713,129 | $181.0K | 0.00% | −23,794−3.2% | Reduced |
| Group One Trading, L.P. | 190,752 | $48.0K | 0.00% | −36,700−16.1% | Reduced |
| BlackRock Inc. | 113,214 | $29.0K | 0.00% | −5,000−4.2% | Reduced |
| Geode Capital Management, LLC | 104,619 | $26.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 102,440 | $26.0K | 0.00% | 00.0% | Unchanged |
| Allred Capital Management, LLC | 47,238 | $11.0K | 0.01% | +10,400+28.2% | Added |
| Northern Trust Corp | 39,414 | $10.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 40,146 | $10.0K | 0.00% | +40,146 | New |
| Virtu Financial LLC | 38,211 | $10.0K | 0.00% | +38,211 | New |
| Renaissance Technologies LLC | 25,833 | $7.00K | 0.00% | +13,200+104.5% | Added |
| State Street Corp | 23,843 | $6.00K | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 19,016 | $4.00K | 0.00% | −10,600−35.8% | Reduced |
| PDS Planning, Inc | 10,565 | $3.00K | 0.00% | 00.0% | Unchanged |
| Hudson Bay Capital Management LP | 11,110 | $3.00K | 0.00% | +11,110 | New |
| Pathstone Family Office, LLC | 10,050 | $2.54K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 8,424 | $2.00K | 0.00% | +5,995+246.8% | Added |
| Wells Fargo & Company | 4,955 | $1.00K | 0.00% | +10.0% | Added |
| Kelly Financial Services LLC | 50 | $13 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 1,050 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,722 | $0 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 266 | $0 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 105 | $0 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 350 | $0 | 0.00% | 00.0% | Unchanged |
| Sound Income Strategies, LLC | 599 | $0 | 0.00% | 00.0% | Unchanged |
| Beacon Capital Management, LLC | 10 | $0 | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −24,217−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −13,510−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −45−100.0% | Sold out |